Sevgi, Duriye Damla
Srivastava, Sunil K.
Wykoff, Charles
Scott, Adrienne W. http://orcid.org/0000-0003-2607-1184
Hach, Jenna
O’Connell, Margaret
Whitney, Jon
Vasanji, Amit
Reese, Jamie L.
Ehlers, Justis P. http://orcid.org/0000-0001-6763-7768
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (K23-EY022947-01A1)
Article History
Received: 4 October 2020
Revised: 22 May 2021
Accepted: 21 June 2021
First Online: 9 August 2021
Competing interests
: SKS receives funding from Gilead, Regeneron, and Allergan; receives compensation as a consultant from Bausch and Lomb and Santen; owns a patent with Leica. CW receives compensation as a consultant from Adverum, Allergan, Apellis, Clearside, EyePoint, Genentech/Roch, Neurotech, Novartis, Opthea, Regeneron, Regenxbio, Samsung, Santen, Alimera Sciences, Allegro, Alynylam, Bayer, Clearside, D.O.R.C., Kodiak, Notal Vision, ONL Therapeutics, PolyPhotonix, and RecensMedical. AWS receives compensation as a consultant from Allergan and Novartis. AV is an employee of ERT. JPE receives funding and compensation as a consultant from Aerpio, Adverum Alcon, Thrombogenics/Oxurion, Regeneron, Stealth, Roche, Genetech, Novartis, and Allergan; receives compensation as a consultant from Roche, Leica, Zeiss, Allegro, Santen and has a patent with Leica.